Peregrine Pharmaceuticals

Patent issued for vasopermeation enhancement technology

Published in Law and Health Weekly, March 27th, 2004

Peregrine Pharmaceuticals (PPHM) announced the issuance of U.S. Patent No. 6,696,276 that covers its vasopermeation enhancement agent (VEA) technology.

The patent, titled "Vasopermeability-Enhancing Conjugates," further expands Peregrine's patent coverage for general concepts of using agents that localize to tumors and induce tumor blood vessels to become more permeable in order to make chemotherapy drugs and diagnostic agents more effective.

Vasopermeation enhancement agents are sensitizing agents that enhance the effectiveness of cancer therapy or diagnosis by allowing a greater amount of an administered drug or diagnostic agent to reach the target...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2004-03-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry